[Pulmonary function tests in asthmatic children in treatment with tulobuterol].
The objective of the present study was to evaluate the effectiveness and tolerance of a new beta-2 agonist, tulobuterol, in children. Fifteen patients with acute asthma were studied, during a period of 21 days. Significant increase in forced vital capacity (FVC), forced expiratory volume in the first second (FEV-1), and forced expiratory flow 25-75% (FEF 25-75%) were observed after treatment with tulobuterol (p less than 0.01). Clinical improvement was evident as measured by a clinical-scale and a functional scale. The only side effect attributable to the drug was a tremor which was observed in three patients.
Pérez-Martini
L
L
Blanco
R A
RA
Heffner
G
G
Ordóñez-Comparini
R
R
D000293:Adolescent; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005540:Forced Expiratory Flow Rates; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D012129:Respiratory Function Tests; D013224:Status Asthmaticus / Q000188:drug therapy / Q000503:physiopathology; D013726:Terbutaline / Q000031:analogs & derivatives* / Q000627:therapeutic use
D001993:Bronchodilator Agents; C010809:tulobuterol; D013726:Terbutaline
Pruebas de función pulmonar en niños asmáticos en tratamiento con tulobuterol.